| Literature DB >> 19513006 |
Thomas J Schmidt1, Amal M M Nour, Sami A Khalid, Marcel Kaiser, Reto Brun.
Abstract
Prompted by results of our previous studies where we found high activity of some sesquiterpene lactones (STLs) against Trypanosoma brucei rhodesiense (which causes East African sleeping sickness), we have now conducted a structure-(in-vitro)-activity study on a set of 40 STLs against T. brucei rhodesiense, T. cruzi, Leishmania donovani and Plasmodium falciparum. Furthermore, cytotoxic activity against L6 rat skeletal myoblast cells was assessed. Some of the compounds possess high activity, especially against T. brucei (e.g. helenalin and some of its esters with IC(50)-values of 0.05-0.1 microM, which is about 10 times lower than their cytotoxic activity). It was found that all investigated antiprotozoal activities are significantly correlated with cytotoxicity and the major determinants for activity are a,b-unsaturated structural elements, also known to be essential for other biological activities of STLs. It was observed, however, that certain compounds are considerably more toxic against protozoa than against mammalian cells while others are more cytotoxic than active against the protozoa. A comparative QSAR analysis was therefore undertaken, in order to discern the antiparasitic activity of STLs against T. brucei and cytotoxicity. Both activities were found to depend to a large extent on the same structural elements and molecular properties. The observed variance in the biological data can be explained in terms of subtle variations in the relative influences of various molecular descriptors.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19513006 PMCID: PMC6254286 DOI: 10.3390/molecules14062062
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of the sesquiterpene lactones under study.
In vitro antiprotozoal and cytotoxic activity of the STL under study (IC50, µM). Each entry represents the mean of two independent measurements.
| Compound |
|
|
|
| Cytotoxicity |
|---|---|---|---|---|---|
|
| 0.052 | 0.695 | n.t. | n.t. | 0.992 |
|
| 0.063 | 0.538 | 0.446 | 0.329 | 0.809 |
|
| 0.105 | 1.568 | 0.837 | 0.700 | 1.030 |
|
| 0.116 | 2.478 | 0.871 | 0.822 | 1.298 |
|
| 0.686 | 21.477 | 3.848 | 3.047 | 8.902 |
|
| 1.415 | 6.928 | >4* | n.t. | 3.056 |
|
| 0.911 | 3.534 | 1.476 | 1.603 | 4.583 |
|
| 0.319 | 1.870 | >4* | n.t. | 2.443 |
|
| 9.275 | 45.833 | n.t. | n.t. | 12.284 |
|
| 6.705 | 20.422 | 12.240 | 6.461 | 4.392 |
|
| 18.346 | 52.744 | 20.602 | 12.143 | 31.917 |
|
| 10.951 | 49.176 | 17.967 | 10.604 | 16.676 |
|
| 19.242 | 60.165 | 14.505 | 27.473 | 31.758 |
|
| 1.174 | 14.657 | 4.257 | 8.943 | 8.429 |
|
| 3.961 | 16.311 | 8.675 | 5.984 | 7.281 |
|
| 13.607 | 44.891 | 11.831 | 10.656 | 21.557 |
|
| 62.081 | >120* | 23.831 | >20* | 178.790 |
|
| 2.919 | 26.220 | 17.642 | 7.825 | 30.203 |
|
| 0.330 | 11.260 | 0.599 | 6.511 | 22.137 |
|
| 15.887 | 38.992 | 14.597 | 12.702 | 19.839 |
|
| 0.638 | 16.083 | 22.047 | 4.961 | 9.429 |
|
| 1.288 | 95.420 | 26.908 | 6.527 | 13.282 |
|
| 162.200 | >120* | 15.400 | >20* | >365* |
|
| 8.205 | >120* | 27.051 | >20* | 427.350 |
|
| 23.621 | 22.263 | >14* | n.t. | 4.483 |
|
| 7.802 | 24.778 | >4* | n.t. | 0.948 |
|
| 10.724 | 24.345 | 11.759 | 9.207 | 8.914 |
|
| 341.480 | >120* | >120* | >20* | 187.120 |
|
| 2.625 | 8.297 | 3.030 | 6.401 | 5.991 |
|
| 1.602 | 17.256 | 8.699 | 10.691 | 10.183 |
|
| 17.806 | 28.911 | 6.008 | 12.056 | 33.185 |
|
| 1.107 | 26.210 | 7.339 | 13.629 | 25.565 |
|
| 1.303 | 16.799 | 15.212 | 6.323 | 10.212 |
|
| 0.388 | 10.665 | 3.556 | 11.895 | 7.238 |
|
| 49.000 | >120* | 35.560 | >20* | 132.600 |
|
| 14.283 | 25.582 | 2.726 | 9.444 | 13.624 |
|
| 0.478 | 15.786 | 5.190 | 6.333 | 7.750 |
|
| 0.942 | 16.492 | 18.204 | 8.812 | 12.970 |
|
| 0.804 | 17.574 | 30.074 | 8.069 | 10.099 |
|
| 0.698 | 11.833 | 17.095 | 6.643 | 6.667 |
|
| 0.008a | 2.000b | 0.270c | 0.248d | 0.012e |
*highest concentration tested, IC50 not determined. n.t.: not tested. amelarsoprol; bbenznidazole; cmiltefosine; dchloroquine; epodophyllotoxin.
Interrelations of antiprotozoal and cytotoxic activity data (Correlation coefficients R of pIC50 data).
| T. b. rhod. | T.cruzi | L. donov. | P. falcip. | L6 cytotox. | |
|---|---|---|---|---|---|
|
| 1.000 | ||||
|
| 0.851 | 1.000 | |||
|
| 0.704 | 0.823 | 1.000 | ||
|
| 0.808 | 0.912 | 0.753 | 1.000 | |
|
| 0.698 | 0.857 | 0.697 | 0.905 | 1.000 |
Statistical parameters of PLS2 models for antitrypanosomal activity (Tbr) and cytotoxicity (L6).
| Model | n var.a | n comp.b | n PCsc | R2 | Q2 | ||
|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||
| 1 | 44 | 40 | 7 | 0.83 | 0.91 | 0.52 | 0.41 |
| 2 | 44 | 39* | 4 | 0.81 | 0.82 | 0.66 | 0.61 |
| 3 | 20 | 39* | 3 | 0.80 | 0.81 | 0.71 | 0.71 |
*compound 24 was omitted since it was found to represent an outlier. a number of variables included; b number of compounds; c number of significant PLS components (latent variables). R2: squared correlation coefficient; Q2: squared correlation coefficient of leave-one-out cross validation.
Figure 2Scatter plots of predicted vs. experimental bioactivity data (pIC50; left: L6 cytotoxicity, right: Tbr activity) as obtained by PLS2 after selection of significant variables [model 3 in Table 3]. Blue: calibration data; red: predictions of leave-one-out cross validation.
Figure 3Regression coefficients of the various descriptors (numbering: see Table 4) in the PLS2 model [model 3 in Table 3] (left: L6 cytotoxicity, right: Tbr activity).
Figure 4Scores (left) and loading weight plots (right) of the various compounds and the descriptor variables, respectively, in the PLS2 model [model 3 in Table 3]. Top: PC2 vs. PC1, Bottom: PC3 vs PC2. In the scores plots, compounds are coloured according to their activity against Tbr (pIC50).
List of molecular descriptors considered in PLS2-QSAR modelling. Descriptors included in the final model [model 3 in Table 3] are highlighted.
| accessible surface area of beta carbons in α,β-unsaturated carbonyl structures | ||
| accessible surface area of α,β-unsaturated carbonyl structures | ||
| 2 | AM1_HOMO | Eigenvalue of highest occupied molecular orbital (MOE/MOPAC/AM1) |
| Eigenvalue of second highest occupied molecular orbital (MOE/MOPAC/AM1) | ||
| 5 | AM1_HOMO2 | Eigenvalue of third highest occupied molecular orbital (MOE/MOPAC/AM1) |
| 6 | AM1_HOMO3 | Eigenvalue of fourth highest occupied molecular orbital (MOE/MOPAC/AM1) |
| Eigenvalue of lowest unoccupied molecular orbital (MOE/MOPAC/AM1) | ||
| 8 | AM1_LUMO1 | Eigenvalue of second lowest unoccupied molecular orbital (MOE/MOPAC/AM1) |
| 9 | AM1_LUMO2 | Eigenvalue of third lowest unoccupied molecular orbital (MOE/MOPAC/AM1) |
| Eigenvalue of fourth lowest unoccupied molecular orbital (MOE/MOPAC/AM1) | ||
| 11 | AM1_dipole | Dipole moment calculated with MOE/MOPAC/AM1 |
| solvent accessible molecular surface area [ | ||
| solvent accessible molecular surface area due to atoms with positive parial charge [ | ||
| 14 | ASA- | solvent accessible molecular surface area due to atoms with negative parial charge [ |
| 15 | ASA_H | solvent accessible molecular surface area due to atoms with hydrophobic properties [ |
| solvent accessible molecular surface area due to atoms with polar properties [ | ||
| fractional solvent accessible molecular surface area calculated as ASA+/ASA [ | ||
| fractional solvent accessible molecular surface area calculated as ASA-/ASA [ | ||
| 19 | FASA_H | fractional solvent accessible molecular surface area calculated as ASA_H/ASA [ |
| 20 | FASA_P | fractional solvent accessible molecular surface area calculated as ASA_P/ASA [ |
| 21 | FCASA+ | Positive charge weighted surface area, ASA+ * maximum positive partial charge [ |
| 22 | FCASA- | Negative charge weighted surface area, ASA- * maximum negative partial charge [ |
| 23 | glob | globularity [ |
| largest standardized dimension [ | ||
| second largest standardized dimension [ | ||
| 26 | std_dim3 | third largest standardized dimension [ |
| log of calculated water solubility [ | ||
| solvation Energy [ | ||
| 29 | logP(o/w) | log of calculated octanol/water partition coefficient [ |
| 30 | SlogP | log of calculated octanol/water partition coefficient [ |
| 31 | ASAN1 | fractional accessible surface area due to atoms in partial charge interval 0 to -0.05 e [ |
| 32 | ASAN2 | fractional accessible surface area due to atoms in partial charge interval -0.05 to -0.1 e [ |
| 33 | ASAN3 | fractional accessible surface area due to atoms in partial charge interval -0.1 to -0.15 e [ |
| 34 | ASAN4 | fractional accessible surface area due to atoms in partial charge interval -0.15 to -0.2 e [ |
| fractional accessible surface area due to atoms in partial charge interval -0.2 to -0.25 e [ | ||
| fractional accessible surface area due to atoms in partial charge interval -0.25 to -0.3 e [ | ||
| 37 | ASAN7 | fractional accessible surface area due to atoms in partial charge interval <-0.30 e [ |
| fractional accessible surface area due to atoms in partial charge interval 0 to 0.05 e [ | ||
| 39 | ASAP2 | fractional accessible surface area due to atoms in partial charge interval 0.05 to 0.1 e [ |
| fractional accessible surface area due to atoms in partial charge interval 0.1 to 0.15 e [ | ||
| fractional accessible surface area due to atoms in partial charge interval 0.15 to 0.2 e [ | ||
| fractional accessible surface area due to atoms in partial charge interval 0.2 to 0.25 e [ | ||
| 43 | ASAP6 | fractional accessible surface area due to atoms in partial charge interval 0.25 to 0.3 e [ |
| 44 | ASAP7 | fractional accessible surface area due to atoms in partial charge interval >0.3 e [ |